HQL-79 is a selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor. It inhibits the synthesis of PGD2 and acts as an anti-allergic agent (Kd: 0.8 μM and IC50: 6 μM). It also shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS.

HQL-79 is a competitive inhibitor against substrate PGH2. HQL-79 is also a non-competitive one against GSH[1].

162641-16-9

C22H27N5O

377.48

HQL-79

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years